1832 Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

1832 Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-427,200	Closed	-$71.4M	–	686
2018 Q3	$71.4M	Buy	427,200 +19,397	+5%	+$2.92M	0.23%	98
2018 Q2	$51.4M	Buy	+407,803	New	+$45.5M	0.17%	115
2017 Q4	–	Sell	-15,068	Closed	-$1.24M	–	714
2017 Q3	$1.24M	Buy	+15,068	New	+$1.19M	﹤0.01%	410
2016 Q3	–	Sell	-752,929	Closed	-$55.2M	–	723
2016 Q2	$55.2M	Hold	752,929	–	–	0.21%	108
2016 Q1	$80.3M	Buy	+752,929	New	+$45.8M	0.2%	120

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

1832 Asset Management's LGND Position: Q4 2018 in Review

1832 Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 427,200 shares — an estimated $71.4M sold.

1832 Asset Management first reported a position in LGND in Q1 2016 and held it in 5 quarters. The position peaked at $80.3M in Q1 2016. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

1832 Asset Management reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
1832 Asset Management sold 427,200 Ligand Pharmaceuticals shares in Q4 2018, an estimated $71.4M.
1832 Asset Management first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 5 quarters.
1832 Asset Management's Ligand Pharmaceuticals position peaked at $80.3M in Q1 2016.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on 1832 Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.